TCGA-HD-7229-01A-11R-2016-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.650
- INTERFERON_GAMMA_RESPONSE+0.530
- IL6_JAK_STAT3_SIGNALING+0.380
- MITOTIC_SPINDLE+0.340
- PROTEIN_SECRETION+0.320
- COMPLEMENT+0.310
- G2M_CHECKPOINT+0.240
- ALLOGRAFT_REJECTION+0.220
- APICAL_SURFACE+0.210
- PI3K_AKT_MTOR_SIGNALING+0.210
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.440
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.420
- MYC_TARGETS_V1-0.380
- NOTCH_SIGNALING-0.340
- MYC_TARGETS_V2-0.330
- MYOGENESIS-0.260
- PEROXISOME-0.260
- FATTY_ACID_METABOLISM-0.250
- PANCREAS_BETA_CELLS-0.200
- ADIPOGENESIS-0.180
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG745 | — | — | 0.801 |
| 2 | TCGA-OR-A5JZ-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.790 |
| 3 | TCGA-BH-A0BW-01A-11R-A115-07 | — | D | 0.757 |
| 4 | TCGA-55-8089-01A-11R-2241-07 | — | cohortA1 | 0.752 |
| 5 | R134 | — | — | 0.752 |
| 6 | SRR8518454 | — | D | 0.747 |
| 7 | TCGA-CV-7427-01A-11R-2081-07 | — | — | 0.737 |
| 8 | C3L-00904 | — | cohortSQ1 | 0.735 |
| 9 | SRR12696760 | — | — | 0.729 |
| 10 | TCGA-XF-A8HD-01A-11R-A36F-07 | — | — | 0.727 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.650 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.530 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.380 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.340 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.320 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.310 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.240 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.220 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.210 | Temsirolimus | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.210 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.210 | Inavolisib | — uncovered |
| HYPOXIA | 0.200 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.170 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.160 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.160 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.150 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.090 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.080 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.080 | Inavolisib | — uncovered |
| APOPTOSIS | 0.070 | Idelalisib | — uncovered |